Lymphoma in patients with rheumatoid arthritis: Association with the disease state or methotrexate treatment

Seminars in Arthritis and Rheumatism

Volumn 26, Issue 6, 1997, Pages 794-804

  Georgescu, L ^a   Quinn, G C ^a   Schwartzman, S ^a   Paget, S A ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

Epidemiology; Immunity; Lymphoma; Methotrexate; Oncogenicity; Rheumatoid arthritis

Indexed keywords

FOLIC ACID; HYDROXYCHLOROQUINE; METHOTREXATE; PREDNISONE; SULINDAC;

ADULT; AGED; B CELL LYMPHOMA; CANCER RISK; CLINICAL ARTICLE; DRUG EFFECT; EPSTEIN BARR VIRUS; FEMALE; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

EID: 0030920729     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-0172(97)80023-6     Document Type: Article

References (98)

1. Annual prescriptions for methotrexate number approximately1.25 million, with an estimated 50-60 percent of these for RA. (Personal communications with Lederle and Dr Weinblatt).
2. Symmons D.P. Prior P. Scott D.L. Brown R. Hakins O. Factors influencing mortality in rheumatoid arthritis J Chronic Dis 39 1986 137 145
3. Weinblatt M.E. Weissman B.N. Holdsworth D.E. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis: 84-month update Arthritis Rheum 35 1992 129 137
4. Weinstein A. Marlowe S. Korn J. Farouhar F. Low-dose methotrexate treatment of rheumatoid arthritis: long-term observations Am J Med 79 1985 331 337
5. Kremer J.M. Phelps C.T. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis: update after a mean of 90 months Arthritis Rheum 35 1992 138 145
6. Furst D.E. Erikson N. Clute L. Koehnke R. Burmeister L.F. Kohler J.A. Adverse experience with methotrexate during 176 weeks of a longterm prospective trial in patients with rheumatoid arthritis J Rheumatol 17 1990 1628 1635
7. Tishler M. Caspi D. Yaron M. Long-term experience with low dose methotrexate in rheumatoid arthritis Rheumatol Int 13 1993 103 106
8. Rustin G.H.S. Rustin F. Dent J. Booth M. Salt S. Bagshawe K.D. No increase in second tumors after cytotoxic chemotherapy for gestational trophoblastic tumors N Engl J Med 308 1983 473 476
9. Bailin P.L. Tindall J.P. Roenigk H.H. Hogan M.D. Is methotrexate therapy for psoriasis carcinogenic? JAMA 232 1975 359 362
10. Stern R.S. Zierler S. Parrish J.A. Methotrexate used for psoriasis and the risk of noncutaneous or cutaneous malignancy Cancer 50 1982 869 872
11. Nyfors A. Jensen H. Frequency of malignant neoplasm in 248 long-term methotrexate treated psoriatics Dermatologica 167 1983 260 261
12. Carmeli Y. Mevorach D. Kaminski N. Raz E. Regression of Kaposi's sarcoma after intravenous immunoglobulin treatment for polymyositis Cancer 72 1994 2859 2861
13. Harrison P.V. Gorst D.W. Fennell S.J. Higgins G.S. Methotrexate, psoriasis, and malignancy Lancet 1 1984 996 997
14. [abstract] Bologna C. Viu P. Jorgensen C. Sany J. Study of 8 cases of cancer observed in 458 rheumatoid arthritis (RA) patients treated with methotrexate (MTX) Arthritis Rheum 38 1995 S206 s2
15. Sany J. Anaya J.M. Lussiez V. Couret M. Combe B. Daures J.P. Treatment of rheumatoid arthritis with methotrexate: a prospective open longterm study of 191 cases J Rheumatol 18 1991 1323 1327
16. Shiroky J.B. Frost A. Skelton J.D. Hoegert D.G. Newkirk M.M. Neville C. Complications of immunosuppression associated with weekly low dose methotrexate J Rheumatol 18 1991 1172 1175
17. Ellman M.H. Hurwitz H. Thomas C. Kozloff M. Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate J Rheumatol 18 1991 1741 1743
18. Kingsmore S.F. Hall B.D. Allen N.B. Rice J.R. Caldwell D.S. Association of methotrexate, rheumatoid arthritis and lymphoma: report of 2 cases and literature review J Rheumatol 19 1992 1462 1465
19. Taillan B. Garnier G. Castanet J. Ferrarin E. Pesce A. Dujardin P. Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate Clin Rheum 12 1993 93 94
20. Kamel O.W. van de Rijn M. Weiss L.M. Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis N Engl J Med 328 1993 1317 1321
21. Cobeta-Garcia J.C. Ruiz-Jimeno M.T. Fontova-Garrofe R. Non-Hodgkin's lymphoma, rheumatoid arthritis and methotrexate (letter) J Rhematol 20 1993 200 202
22. Morris C.R. Morris A.J. Localized lymphoma in a patient with rheumatoid arthritis treated with parenteral methotrexate (letter) J Rheumatol 12 1993 1272 1273
23. Le Goff P. Koreichi A. Saraux A. Baron D. Lymphoma in a patient under low-dose methotrexate for rheumatoid arthritis: a new case (letter) Rev Rhum Mal Osteoartic 61E 1994 330 331
24. Zimmer-Galler I. Lie J.T. Choroidal infiltrates as the initial manifestation of lymphoma in rheumatoid arthritis after treatment with low-dose methotrexate Mayo Clin Proc 69 1994 258 261
25. Kamel O.W. van de Rijn M. LeBrun D.P. Weiss L.M. Warnke R.A. Dorfman R.E. Lymphoid neoplasms in patients with rheumatoid arthritis and dermatomyositis: frequency of Epstein-Barr virus and other features associated with immunosuppression Hum Pathol 25 1994 638 643
26. Lioté F. Pertuiset E. Cochand-Priollet B. D'Agay M.F. Domlaret H. Numeric P. Methotrexate related B lymphoproliferative disease in a patient with rheumatoid arthritis: role of Epstein-Barr virus infection J Rheumatol 22 1995 1174 1178
27. (Suppl) Davies J.M.S. Kremer J.M. Furst D.E. Mason V. Eastman A. Lymphomatous changes during methotrexate therapy [abstract] Arthritis Rheum 38 1995 S204 s2
28. Bachman T.R. Sawitzke A.D. Perkins S.L. Ward J.H. Cannon G.W. Methotrexate associated lymphoma in patients with rheumatoid arthritis: report of two cases Arthritis Rheum 39 1996 325 329
29. van de Rijn M. Michael L.C. Variakojis D. Warnke R.A. Chang P.P. Kamel O.W. Epstein-Barr virus clonality in lymphomas occurring in patients with rheumatoid arthritis Arthritis Rheum 39 1996 638 642
30. Moder K.G. Tefferi A. Cohen M.D. Menke D.M. Luthra H.S. Hematologic malignancies and the use of methotrexate in rheumatoid arthritis: a retrospective study Am J Med 99 1995 276 289
31. [abstract] Williams C.A. Block D.A. Sibley J. Lymphoma and leukemia in rheumatoid arthritis: a matched case-control study in the ARAMIS (arthritis, rheumatism and aging medical information system) population (Suppl) Arthritis Rheum 38 1995 S204 s2
32. (letter) Shiroky J.B. Newkirk M.M. Reversible lymphomas N Engl J Med 329 1993 1657 1658
33. Penn I. Why do immunosuppressed patients develop cancer? Crit Rev Oncog (United States) 1 1989 27 52
34. Penn I. The changing pattern of posttransplant malignancies Transplant Proc 23 1991 1101 1103
35. Penn I. Cancers complicating organ transplantation N Engl J Med 323 1990 1767 1769
36. Biemer J.J. Malignant lymphomas associated with immunodeficiency states Ann Clin Lab Sci 20 1990 175 191
37. Hamilton D.S. Pallesen G. Franzmann M.B. AIDS-related lymphoma: histopathology, immunophenotype, and association with Epstein-Barr virus as demonstrated by in situ nucleic acidhybridization Am J Pathol 138 1991 149 163
38. Nalesnic M.A. Makowka L. Starzl T.E. The diagnosis and treatment of posttransplant lymphoproliferative disorders Curt Probl Surg 25 1988 367 472
39. Knowles D.M. Chamulak G.A. Subar M. Lymphoid neoplasia associated with the acquired immunodeficiency syndrome (AIDS) Ann Intern Med 108 1988 744 753
40. Cash J.M. Klippel J.H. Is malignancy a major concern in rheumatoid arthritis patients? J Clin Rheum 1 1995 14 22
41. Symmons D.P. Neoplasms of the immune system in rheumatoid arthritis Am J Med 78 Suppl 1A 1985 22 28
42. Staal S.P. Ambinder R. Beschorner W.E. Hayward G.S. Mann R. A survey of Epstein-Barr virus DNA in lymphoid tissue: frequent detection in Hodgkin's disease Am J Clin Pathol 91 1989 1 5
43. Starzl T.E. Nalesnik M.A. Porter K.A. Ho M. Iwatsuki S. Griffith B.P. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy Lancet 1 1984 583 587
44. Kassan S.S. Thomas T.L. Moutsopoulos H.M. Increased risk of lymphoma in sicca syndrome Ann Intern Med 89 1978 888 892
45. Wotherspoon A.C. Ortiz-Hidalgo C. Falzon M.R. Isaacson P.G. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma Lancet 338 1991 1175 1176
46. Prior P. Cancer and rheumatoid arthritis: epidemiologic considerations Am J Med 78 Suppl 1A 1985 15 21
47. Isomaki H.A. Hakulinen T. Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis J Chron Dis 31 1978 691 696
48. Gridley G. McLaughlin J.K. Ekbom A. Incidence of cancer among patients with rheumatoid arthritis J Natl Cancer Inst 85 1993 307 311
49. Zulman J. Jaffe R. Talal N. Evidence that the malignant lymphoma of Sjögren's syndrome is a monoclonal B-cell neoplasm N Engl J Med 299 1978 1215 1220
50. Shirai T. Hirose S. Okada T. Nishimura H. CD5+ B cells in autoimmune disease and lymphoid malignancy Clin Immunol Immunopathol 59 1991 173 186
51. Burastero S.E. Casali P. Wilder R.L. Notkins A.L. Monoreactive high affinity and polyreactive low affinity rheumatoid factors are produced by CD5+ B cells from patients with rheumatoid arthritis J Exp Med 168 1988 1979 1992
52. Kuryliszyn-Moskal A. Comparison of blood and synovial fluid lymphocytes subsets in rheumatoid arthritis and osteoarthritis Clin Rheumatol 14 1995 43 50
53. Sakane T. Murakawa Y. Takeno M. Shigeki T. Nagatuki H. Miki T. T cell interactions in active rheumatoid arthritis: insights from human autologus mixed reaction as a model of T cell activation cascade Clin Exp Immunol 85 1991 55 60
54. Jones B.M. Cheng I.K. Wong R.W. Aberrant T-regulation in rheumatoid arthritis and IgA nephropaty affects CD5+ and CD5− B lymphocytes equally Clin Exp Immunol 86 1991 212 218
55. Brown-Galatola C.H. Hall N.D. Impaired suppressor cell activity due to surface sulphydryl oxidation in rheumatoid arthritis Br J Rheumatol 31 1992 599 603
56. Mirza N.M. Relias V. Yunis E.J. Pachas W.N. Dasgupta J.D. Defective signal transduction via T-cell receptor-CD3 structure in T cells from rheumatoid arthritis patients Hum Immunol 36 1993 91 98
57. Allen M.E. Young S.P. Michell R.H. Bacon P.A. Altered T lymphocyte signaling in rheumatoid arthritis Eur J Immunol 25 1995 1547 1554
58. Chen E. Keystone E.C. Fish E.N. Restricted cytokine expression in rheumatoid arthritis Arthritis Rheum 36 1993 901 910
59. Wu C.H. Yeng K.C. Lan J.L. Mycobacterium tuberculosis antigen, interleukin-2 and interleukin-2 inhibitor in patients with rheumatoid arthritis Immunol Invest 24 1995 957 964
60. Depper J.M. Bluestein H.G. Zvaifler N.J. Impaired regulation of Epstein-Bar virus induced lymphocyte proliferation in rheumatoid arthritis due to a T cell defect J Immunol 127 1981 1899 1902
61. Tosato G. Steinberg A.D. Yarchoan R. Abnormally elevated frequency of Epstein-Barr virus-infected B cells in the blood of patients with rheumatoid arthritis J Clin Invest 73 1984 1789 1795
62. Kahan A. Kahan A. Amor B. Menkes C.J. Different defects of T cell regulation of Epstein-Barr virus-induced B cell activation in rheumatoid arthritis Arthritis Rheum 28 1985 961 970
63. Purtilo D.T. DeFlorio D. Hutt L.M. Variable phenotypic expression of an X-linked recessive lymphoproliferative syndrome N Engl J Med 297 1977 1077 1081
64. Fox R.I. Martin Lotz Rhodes G. Vaughan J.H. Epstein Barr virus in rheumatoid arthritis Rheum Dis Clin North Am 11 1985 665 898
65. Rowe M. Peng-Pilon M. Huen D.S. Upregulation of bcl -2 by the Epstein-Barr virus latent membrane protein LMP1: a B-cell-specific response that is delayed relative to NF-kB activation and to induction of cell surface markers J Virol 68 1994 5602 5612
66. Gregory C.D. Dive C. Henderson S. Activation of Epstein-Barr virus latent genes protects human B cells from death by apoptosis [letter] Nature 349 1991 612 614
67. Wang D. Liebowitz D. Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells Cell 43 1985 831 840
68. Newkirk M.M. Watanabe Duffy K.N. Leclerc J. Lambert N. Shiroky J.B. Detection of cytomegalovirus, Epstein-Barr virus and herpes virus-6 in patients with rheumatoid arthritis with or without Sjögren's syndrome Br J Rheumatol 33 1994 317 322
69. Young C.L. Adamson T.C. III Vaughan J.H. Fox R.I. Immunohistological characterization of synovial membrane lymphocytes in rheumatoid arthritis Arthritis Rheum 27 1984 32 39
70. Dobloug J.H. Forte O. Kvien T.K. Egeland T. Degre M. Natural killer cell activity of peripheral blood, synovial tissue lymphocytes from patients with rheumatoid arthritis and juvenile rheumatoidarthritis Ann Rheum Dis 41 1982 490
71. Fox R.I. Fong S. Tsoukas C. Vaughan J.H. Characterization of recirculating lymphocytes in rheumatoid arthritis patients: selective deficiency of natural killer cells in thoracic duct lymph J Immunol 132 1984 2883 2887
72. Sieber S.M. Adamson R.H. Toxicity of antineoplastic agent in man: chromosomal aberrations, antifertility effects, congenital malformations, and carcinogenic potential Adv Cancer Res 22 1975 57 155
73. Ryan T.J. Boddington M.M. Spriggs A.I. Chromosomal abnormalities produced by folic acid antagonists Br J Dermatol 77 1965 546 555
74. Jensen M.K. Nyfors A. Cytogenetic effect of methotrexate on human cells in vivo: comparison between results obtained by chromosome studies on bone marrow cells and bloodlymphocytes and by the micronucleus test Mutat Res 64 1979 339 343
75. Melnik J. Duffy D.M. Sparkes R.S. Human mitotic and meiotic chromosome damage following in vivo exposure to methotrexate Clin Genet 2 1971 28 31
76. Benedict W.F. Banerjee A. Gardner A. Jone P.A. Induction of morphological transformation in mouse C3H/10T1/2 clone 8 cells and chromosomal damage in hamster A (T1)C1-3 cells by cancer chemotherapeutic agents Cancer Res 37 1977 2202 2208
77. Banjeree A. Benedict W.E. Production of sister chromatid exchanges by various cancer chemotherapeutic agents Cancer Res 39 1979 797 799
78. Lindskov R. Wulf H.C. Wantzin G.L. Niebuhr E. Sister chromatid exchange in patients treated with methotrexate for psoriasis J Invest Dermatol 82 1984 458 459
79. Goodman L.S. Gilman A. The pharmacological basis of therapeutics 1955 MacMillan New York 1430
80. Johnson Carol A. Russell A.S. Kovithavongs T. Dasgupta M. Measures of immunologic and inflammatory response in vitro in rheumatoid patients treated with methotrexate J Rheumatol 12 1986 294 296
81. Yunis J.J. Soreng A.L. Constitutive fragile sites and cancer Science 226 1984 1199 1204
82. Melief C.J.M. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes Adv Cancer Res 58 1992 143 175
83. Hanna N. Fidler I.J. Role of natural killer cells in the destruction of circulating tumor emboli J Natl Cancer Inst 65 1980 801 809
84. Hersh E.M. Carbone P.P. Wong V.G. Freiroch E.J. Inhibition of the primary immune response in man by antimetabolites Cancer Res 25 1965 997 1002
85. Fillingame R.H. Jorstad C.M. Morris D.R. Increased cellular levels of spermidine or spermine are required for optimal DNA synthesis in lymphocytes activated by concanavalin A Proc Natl Acad Sci U S A 72 1975 4042 4045
86. Bowlin T.L. McKown B.J. Schroeder K.K. Methylacetylenic putrescine (MAP) an inhibitor of polyamine biosynthesis reduces the frequency and cytolytic activity of alloantigen-induced lyt 2.2 positive lymphocytes in vivo Int J Immunopharmacol 11 1989 259 265
87. O'Callaghan J.W. Bretscher P. Russell A.S. The effect of low dose chronic intermittent parental methotrexate on delayed type hypersensitivity and acute inflammation in a mouse model J Rheumatol 13 1986 710 714
88. Bowlin T.L. McKown B.J. Babcock G.F. Sunkara P.S. Intracellular polyamine biosynthesis is required for interleukin 2 responsiveness during lymphocyte mitogenesis Cell Immunol 106 1987 420 427
89. Pasquali J.L. Mamont P.S. Weryha A. Knapp A.M. Biervague A. Siat M. Immunosuppressive effects of (2R,5R)-6heptyne-2,5-diamine, an inhibitor of polyamine synthesis. I. Effects on mitogen-induced immunoglobulin production in human cultured lymphocytes Clin Exp Immunol 72 1988 141 144
90. Olsen N.J. Murray L.M. Antiproliferative effects of methotrexate on peripheral blood mononuclear cells Arthritis Rheum 32 1989 378 385
91. (suppl) Nakajima A. Hakoda M. Yamanaka H. Kamatani N. Kashiwazaki S. Methotrexate (MTX) induces apoptosis in activated T cells [abstract] Arthritis Rheum 38 1995 S192
92. Weinblatt M.E. Trentham D.E. Fraser P.A. Long term prospective trial of low dose methotrexate in rheumatoid arthritis Arthritis Rheum 31 1988 167 175
93. (suppl) Kremer J.M. Lymphocyte subset analysis after long-term methotrexate therapy for rheumatoid arthritis [abstract] Arthritis Rheum 29 1986 S75
94. O'Meara A. Headon B. Reen D.J. Effect of methotrexate on the immune responses in children with acute lymphatic leukemia Immunopharmacology 9 1985 33 38
95. Boerbooms A.M.T. Kerstens P.J.S.M. van Loenhout J.W.A. Mulder J. van de Putte L.A. Infections during low-dose methotrexate treatment in rheumatoid arthritis Semin Arthritis Rheum 24 1995 411 421
96. Barich L.L. Schwartz J. Barich D. Oral methotrexate in mice: a co-carcinogenic as well as anti-tumor agent to methylcholanthrene-induced cutaneous tumors J Invest Dermatol 39 1962 615 619
97. Rustia M. Shubick P. Life-span carcinogenicity tests with 4-amino-N10-methylpteroylglutamic acid (methotrexate) in Swiss mice and Syrian golden hamsters Toxicol Appl Pharmacol 26 1973 329
98. Tugwell P. Pincus T. Yocum D. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis N Engl J Med 333 1995 137 141